Memory center

Damian, Daniel; Rouaud, Olivier; Draganski, Bogdan; Brioschi-Guevara, Andrea; Bortolotti, M.; Laouadi, Marie-Hélène; Démonet, Jean‐François

doi:10.1177/2514183x18773482

Cited by 6 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We therefore performed a 10-year retrospective analysis on PPA patients from the Leenaards Memory Center in Lausanne, Switzerland, 6 from 2013 to 2023, and identified, based on the inclusion and exclusion criteria of the Clarity AD trial, 1 the number of PPA patients (all phenotypes combined) that could benefit from lecanemab treatment.…”

Section: Don't Forget Primary Progressive Aphasia For Anti-amyloid Dr...mentioning

confidence: 99%

Don't forget primary progressive aphasia for anti‐amyloid drugs: An estimation of eligible patients from the Lausanne Memory Center registry

Hausmann

Chiabotti

Nasuti

et al. 2023

Alzheimer's & Dementia

Self Cite

View full text Add to dashboard Cite

The study recently published on the clinical effect of lecanemab in early Alzheimer's disease (AD) only includes patients with amnestic presentation. However, a significant portion of AD patients presents a non‐amnestic phenotype of AD, such as primary progressive aphasia (PPA) and could benefit of rather than on lecanemab. Therefore, we conducted a 10‐year retrospective study at the Leenaards Memory Center in Lausanne (Switzerland) to identify how many PPA patients would be eligible for lecanemab. Among 54 patients with PPA, we identified 11 (20%) eligible patients. Furthermore, almost half of the 18 patients with logopenic variant would be eligible for lecanemab treatment.

show abstract

Section: Don't Forget Primary Progressive Aphasia For Anti-amyloid Dr...mentioning

confidence: 99%

Don't forget primary progressive aphasia for anti‐amyloid drugs: An estimation of eligible patients from the Lausanne Memory Center registry

Hausmann

Chiabotti

Nasuti

et al. 2023

Alzheimer's & Dementia

Self Cite

View full text Add to dashboard Cite

show abstract

“…Les résultats rapportés ici sont basés sur des données statistiques agrégées, issues des systèmes de gestion de l'activité du CLM. 3 Seuls les résultats des patients âgés de 65 ans et plus ont été analysés sur la période 2013-2019, sachant que l'année 2013 (date de l'ouverture du CLM) semble peu représentative de l'activité du centre. L'information à propos de l'avis formulé a été recueillie soit au sein du rapport neuropsychologique, soit au sein de notre système d'information.…”

Section: Introductionunclassified

Aptitude cognitive à la conduite automobile : retour d’expérience du Centre Leenaards de la Mémoire

Carlier¹,

Démonet²,

Rouaud³

2021

Revue Médicale Suisse

Self Cite

View full text Add to dashboard Cite

Les troubles cognitifs peuvent interférer avec l'aptitude à la conduite automobile. Une hausse des demandes d'évaluation ciblée sur cet aspect est observée au Centre Leenaards de la Mémoire. Les modifications de la loi pourraient être un facteur explicatif. Les avis formulés en 2019 sont majoritairement défavorables chez les patients présentant des troubles cognitifs dus à une maladie d'Alzheimer ou une pathologie apparentée, mais jamais en lien avec le vieillissement seul. Les avis défavorables sont fréquents avant l'âge de 75 ans. Chaque situation est donc unique et chaque décision prise se base non pas sur l'âge du patient, ni sur le diagnostic étiologique, mais sur le profil cognitif. Nous abordons dans cet article les raisons d'un avis défavorable et les discutons dans le contexte des missions de notre centre. Cognitive fitness to drive : feedback at Leenaards Memory CentreCognitive impairment can interfere with the fitness to drive. An increase in requests to assess this aspect is observed at Leenaards Memory Centre. Changes in the law could be an explanatory factor. The views formulated in 2019 are mainly unfavorable because all the patients present cognitive disorders, generally attributed to Alzheimer's disease or a related disorder, but never linked with aging only. Moreover, unfavorable views are frequently expressed before the age of 75. Therefore, each patient is unique, and each decision is based neither on the patient's age or his diagnosis, but rather on his cognitive profile. In this article we discuss the reasons for an unfavorable view and discuss them in the context of the tasks of our centre.

show abstract

A nation-wide initiative for brain imaging and clinical phenotype data federation in Swiss university memory centres

Draganski

Kherif

Damian

et al. 2019

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of review The goal of our nation-wide initiative is to provide clinicians intuitive and robust tools for accurate diagnosis, therapy monitoring and prognosis of cognitive decline that is based on large-scale multidomain data. Recent findings We describe a federation framework that allows for statistical analysis of aggregated brain imaging and clinical phenotyping data across memory clinics in Switzerland. The adaptation and deployment of readily available data capturing and federation modules is paralleled by developments in ontology, quality and regulatory control of brain imaging data. Our initiative incentivizes data sharing through the common resource in a way that provides individual researcher with access to large-scale data that surpasses the data acquisition capacity of a single centre. Clinicians benefit from fine-grained epidemiological characterization of own data compared with the rest additional to intuitive tools allowing for computer-based diagnosis of dementia. Finally, our concept aims at closing the loop between group-level results based on aggregate data and individual diagnosis by providing disease models, that is, classifiers for neurocognitive disorders that will enable the computer-based diagnosis of individual patients. Summary The obtained results will inform recommendations on best clinical practice in all relevant fields focusing on standardization and interoperability of acquired data, privacy protection framework and ethical consideration in the context of evolutive pathology.

show abstract

Memory center

Cited by 6 publications

References 25 publications

Don't forget primary progressive aphasia for anti‐amyloid drugs: An estimation of eligible patients from the Lausanne Memory Center registry

Don't forget primary progressive aphasia for anti‐amyloid drugs: An estimation of eligible patients from the Lausanne Memory Center registry

Aptitude cognitive à la conduite automobile : retour d’expérience du Centre Leenaards de la Mémoire

A nation-wide initiative for brain imaging and clinical phenotype data federation in Swiss university memory centres

Contact Info

Product

Resources

About